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Thromboxane stimulation of mesangial cell fibronectin synthesis
is signalled by protein kinase C and modulated by cGMP
REBECCA K. STUDER, PATRICIA A. CRAVEN, and FREDERICK R. DERUBERTIS
Department of Medicine, VA Medical Center and University of Pittsburgh, Pittsburgh, Pennsylvania, USA
Thromboxane stimulation of mesangial cell fibronectin synthesis is
signalled by protein kinase C and modulated by cGMP. Thromboxane
(TX) has been implicated in the pathogenesis of glomerulosclerosis in
several models of glomerular injury. In the present study, we examined the
role of the protein kinase C (PKC) signalling system in expression of the
action of the TXA2/PGH2 analogue U-46619 to stimulate fibronectin (Fn)
synthesis in cultured rat mesangial cells (MC), and the influence of cGMP
on this MC response. U-46619 activated PKC and enhanced Fn synthesis
in MC in a time and concentration dependent fashion. Both responses to
U-46619 were blocked by GF 109203X, a selective inhibitor of PKC
activity, as well as by calphostin C and staurosporine, PKC inhibitors
structurally distinct from GFX. Down-regulation of PKC by prior sus-
tained exposure of MC to 0.5 rM phorbol myristate acetate similarly
blocked increases in Fn synthesis induced by U-46619. The TXA2/PGH2
receptor antagonist Sq-29548 also prevented activation of PKC and
stimulation of Fn synthesis by U-46619, consistent with transduction of
these responses via specific high affinity TXA2/PGH2 receptors on MC.
Addition of exogenous 8-Br-cGMP or stimulation of endogenous cGMP
generation with atrial natriuretic peptide (ANP) suppressed both U-46619
activation of PKC and stimulation of Fn synthesis. cGMP did not alter
TXA2/PGH2 receptor number or affinity in MC, but significantly sup-
pressed phorbol ester activation of PKC. Thus, cGMP inhibition of
U-46619 actions is expressed at steps distal to TX receptor binding and
may involve effects at and proximal to activation of PKC. Interactions
between the PKC and cGMP cellular signalling systems may be important
determinants of MC matrix protein production in response to TX.
Thromboxane (TX) has been implicated in the pathogenesis of
glomerular injury in diabetes and other nephropathies [1, 2]. In
the streptozotocin diabetic rat, increased glomerular TX produc-
tion contributes to the development of albuminuria, the decline in
GFR, and mesangial expansion and basement membrane thick-
ening in the glomerulus [3—5]. Ledbetter et al [6] found that
inhibition of TX synthesis halted the progression of albuminuria
and prevented the increase in renal cortical type IV collagen
mRNA in non-insulin dependent diabetic mice. The mechanisms
by which TX mediates glomerular injury are not known. However,
recent studies have demonstrated direct actions of TX on mesang-
ial cells that may be relevant to the development of glomerulo-
sclerosis. Thus, Bruggeman et al [7, 8] found that stable throm-
boxane/prostaglandin endoperoxide (TXA2/PGH2) analogues
increased the production of extracellular matrix components,
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including fibronectin (Fn), in cultured human mesangial cells
(MC). Mene et a! [9] demonstrated that TX modulates protein
synthesis in these cells, and we have previously observed matrix Fn
accumulation in rat MC incubated with high glucose concentra-
tions and the stable TX analogue U-46619 [10].
High affinity receptors for TXA2IPGH2 have been identified in
cultured MC [11, 12]. TX binds to these receptors on the plasma
membrane, activates phospholipase C, increases inositol phos-
phate turnover, elevates cytosolic calcium and diacylglycerol, and
activates protein kinase C (PKC) [11, 13, 14]. Although the
increase in cytosolic calcium induced by TX has been correlated
with MC contraction, the signalling pathway involved in TX
stimulation of matrix protein synthesis in MC has not been
evaluated. In the present study, we examined the role of PKC in
the expression of the action of U-46619 to increase MC synthesis
of Fn. We also assessed potential interactions between cGMP and
TX in the modulation of MC synthesis of Fn,
Methods
Isolation and culture of MC
MC lines were established from glomeruli of 120 to 160 g
female Sprague-Dawley rats by the graded sieving technique as
previously reported [10]. They were maintained in RPMI-1640
medium containing 15% fetal calf serum (FCS), 100 U/mI peni-
cillin, 100 Jml streptomycin, 5 g/ml insulin, 5 jkg/ml trans-
ferrin, and 5 ng/ml sodium selenite at 37°C in 5% CO2 and 95%
air. Passages 3 to 8 were used in this series of experiments, since
we have previously found that high affinity binding of the TX
antagonist Sq-29548 was reduced in MC passages greater than 8
[12]. MC were grown to confluence in 12 or 24 well plates and
FCS was reduced to 1% before addition of U-46619 and other
agents.
Fn synthesis
Fn synthesis was measured as 35S-Methionine ([35S]-Met) in-
corporated into immunoprecipitable material extracted from the
cells plus matrix and the media. MC were grown to confluence,
FCS reduced to 1%, and the cells exposed to U-46619 and other
agents as described in the figure legends. The MC were washed
with phosphate buffered saline (PBS), 25 pCi/mI methionine-
cysteine-deficient RPMI-1640 containing [35S]-Met (Tran35S-la-
bel; ICN, Irvine, California, USA) was added, and incubation
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continued for four hours. [35S]-Met labeled Fn was immunopre-
cipitated with human fibronectin antiserum (Collaborative Re-
search Inc., Bedford, Massachusetts, USA) and assayed as previ-
ously described [10]. The data are expressed as dpm/103 cells or
Ipg protein, determined using a Bicinchoninic acid protein assay
kit (Sigma Chemical Co., St. Louis, Missouri, USA). In prelimi-
nary experiments, the content of labeled immunoprecipitable Fn
in the media after the four hour pulse label was less than 10% of
that in the cell plus matrix fraction. After 24 hours of exposure to
1 LM U-46619, the percentage of {35S-Fn] in the medium was 3.9
0.5 versus 5.3 0.7% (N = 6) for vehicle treated cells. The
1.4% decrease in release of Fn into the medium observed in the
presence compared to the absence of U-46619 was significant
(paired t-test, P = 0.017). However, inclusion of data from the
media fractions did not alter our results or conclusions based on
analysis of the cell plus matrix fraction alone. Accordingly, only
changes in the cell plus matrix fraction were routinely monitored
and are reported in the present study.
PKC activily
In situ PKC activity was determined as described previously
[10]. Briefly, MC were grown to confluence, deprived of serum for
24 hours, and labeled with [32P]-orthophosphate for four hours.
The cells were exposed to test agents as described in the figure
legends, and the acid soluble 80 kDa myristoylated alanine rich C
kinase substrate (MARCKS) protein extracted and separated by
electrophoresis. The 80 kDa protein substrate was identified as a
member of the MARCKS family of proteins by immunoprecipi-
tation as previously reported [101. The data are expressed as
density units calculated as the ratio of the phosphorylation of the
80 kDa MARCKS protein, a specific PKC substrate, to a 40 kDa
reference protein, whose phosphorylation did not change under
any of the conditions studied. In some experiments the effects of
2 xM of the bisindolymaleimide, GF 109203X (GFX), a relatively
selective inhibitor of PKC [15], was examined. GFX does not
affect receptor tyrosine kinases, and has an IC50 for phosphorylase
kinase and cAMP dependent protein kinase which are 70 and 200
times greater than the IC50 for PKC [15].
Assessment of TXA2IPGH2 receptors
MC were grown to confluence, FCS decreased to 1% for 24
hours, and some of the cells exposed to 1 .tM 8-Br-cGMP or
8-Br-Guanosine for 60 minutes or 24 hours; equilibrium binding
of [3H] Sq-29548 ([3H]-Sq) (NEN, Boston, Massachusetts, USA)
was then determined as previously reported [12]. Briefly, MC
monolayers were washed three times with PBS, incubated for 60
minutes with 10 nM [3H] Sq, and specific binding determined by
subtraction of binding to cells in the presence of 50 jxM non-
radioactive Sq. To determine the affinity of the TXA2/PGH2
receptors by Scatchard analysis, concentrations of Sq from 0.1 to
20 n were used, as previously reported [12].
cGMP content
MC were grown with or without added test agents as indicated
in the figure legends. The media was removed, cells washed with
PBS and the cGMP in the cell layer was extracted with sodium
acetate buffer, pH 6.2. cGMP was determined by radioimmuno-
assay, as previously reported [161.
Statistics
Experiments were performed at least three times and data are
presented as mean values SE. In a given MC culture, each
incubation condition was represented by either duplicate or
triplicate wells. Replicates from a single culture were entered as
one value for statistical analysis. ANOVA was performed to
compare multiple groups and the significance of differences
between any two mean values was determined by Student's t-test.
Materials
GFX was obtained from Calbiochem (San Diego, California,
USA). Other reagents were from sources noted above or as
previously reported [10, 16].
Results
As shown in Figure 1, a 24 hour exposure of MC to 1 LM
U-46619 stimulated Fn synthesis approximately twofold. U-46619
did not change cell number (vehicle control = 1.0 ,± 0.2 x i0
cells/well; U-46619 = 1.05 0.1) or cell-matrix protein content
(vehicle control = 0.46 0.07 g/iO3 cells; U-46619 = 0.45
0.06) after 24 hours. Thus, the U-46619 stimulated increases in Fn
synthesis were significant whether expressed as a function of
either culture protein content or MC number (Fig. 1). The
ethanol vehicle of U-46619 alone did not alter Fn synthesis (not
shown). The time course of the effect of 1 jLM U-46619 on Fn
synthesis by MC is shown in Figure 2. U-46619 significantly
increased Fn synthesis by approximately 50% after only five hours
of exposure; Fn synthesis remained increased relative to control
through 72 hours of exposure to U-46619. Stimulation of Fn
synthesis by U-46619 after 72 hours was significantly higher than
with shorter exposure times to this agent.
Figure 3 depicts the concentration response relationships be-
tween U-46619 and Fn synthesis (Fig. 3A) or PKC activity (Fig.
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Fig. 1. Effect of U-46619 on mesangial cell fibronectin synthesis. Mesangial
cells were grown to confluence, medium FCS decreased to 1% for 24
hours, and U-46619 () or its ethanol vehicle (0.37%) (E) added.
Fibronectin synthesis was determined after 24 hours exposure to U-46619
or vehicle. Values are means SE (N = 6). *P < 0.05 vs. vehicle control.
Fig. 2. Time course of the effect of U-46619 on mesangial cell fibronectin
synthesis. Mesangial cells were treated as described in Figure 1 and
fibronectin synthesis determined after exposure to 1 M U-46619 or its
vehicle for the times shown. All cells were cultured for 72 hours in 1% FCS
medium. U-46619 or vehicle was present for the terminal periods of the
culture indicated. Values are expressed as the ratio of incorporation of
[35S]-Met into fibronectin in cells exposed to U-46619 to that of cells
cultured with vehicle for the same time period. Values are means SE
(N = 4). p < 0.05 vs. time zero; +P < 0.05 comparing 72 hours exposure
to earlier exposure times (5 to 48 hours).
3B). Although there were small increases in both these parame-
ters in response to 0.01 M U-46619, differences from the vehicle
control were statistically significant only at concentrations from
0.1 to 10 pvi; 1 M U-46619 induced maximal increases in both
parameters. In additional experiments, activation of PKC in
response to U-46619 was independently examined as transloca-
tion of enzyme activity to the membrane bound cell fraction, as
previously described [17]. MC were grown to confluence, medium
serum reduced to 1% for 24 hours, and the soluble and particulate
PKC activity assayed 15 minutes after addition of 1 sMU-466l9 or
ethanol vehicle. U-46619 increased the fraction of PKC activity
associated with particulate cell fraction from 7 2 to 14 2% of
total (soluble plus particulate; N = 5, P < 0.05), and proportion-
ately decreased soluble PKC, a change consistent with enzyme
activation. Figure 4 shows the effect of exposing MC to the
TXA2/PGH2 receptor antagonist Sq-29548 for 15 minutes before
the addition of 1 p.M U-46619. Sq blocked U-46619 stimulation of
both Fn synthesis and activation of PKC, a finding indicative of
transduction of these actions of U-46619 via specific, high affinity
TXA2/PGH2 receptors on MC.
The effects of the PKC inhibitor GFX on Fn synthesis and PKC
activity are shown in Figure 5. GFX did not alter basal MARCKS
protein phosphorylation or Fn synthesis, but blocked responses of
both these parameters to U-46619. In separate experiments, 2 p.M
GFX did not alter basal MARCKS protein phosphorylation, (0.20
0,1 density units) but effectively inhibited activation of PKC by
a maximal stimulatory concentration of PDBu (0.1 p.M PDBu, 0.49
Fig. 3. Concentration response relationships of U-46619 actions on mesang-
ial cell (A) fibronectin synthesis, and (B) protein kinase C activily. (A)
Mesangial cells were treated as described in Figure 1 and fibronectin
synthesis determined after a 24 hour exposure to U-46619. (B) Mesanial
cells were grown as in (A), and the cells were labeled with [3P1-
orthophosphate for 4 hours. In situ phosphorylation of the 80 kDa protein
was then evaluated 15 minutes after addition of the concentrations of
U-46619 shown. Data are expressed as density units, calculated as the ratio
of phosphorylation of 80 kDa MARCKS protein to phosphorylation of 40
kDa reference protein. Values are means SE (N = 5). p < 0.05 vs. no
addition.
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Fig. 4. Inhibition of U-46619 stimulated mesangial cell fibronectin synthesis
(A) and protein kinase C activity (B) by the TX42IPGH2 receptor antagonist
Sq 29548. Mesangial cells were treated as described in Figure 3. The cells
were exposed to 50 gM Sq 29548 or its ethanol vehicle (0.4%) for 15
minutes before the addition of U-46619 () or its vehicle (D). Values are
means se (N = 4). P C 0.05 vs. vehicle control. +P C 0.05 vs.
corresponding value without Sq.
0.1 density units; PDBu + 2 JIM GFX, 0.21 0.1; N = 5, P <
0.05). A 24 hour exposure of MC to 2 JIM GFX did not adversely
affect cell viability as assessed by trypan blue staining, or cell
number/well after 24 hours (viable cell number ratio of GFXJ
vehicle control = 1.05 0.11, N 5). The PKC inhibitors
staurosporine (50 gM) and caiphostin C (0.2 gM) also blocked
increases in Fn synthesis induced by U-46619 (not shown). The
potential role of PKC in signalling U-46619 stimulation of Fn
synthesis was further tested in MC exposed to a high concentra-
0.
GFX GFX
vehicle 2pM
Fig. S. Effect of the protein kinase C inhibitor GF 109203X (GFX) on
U-46619 activation of mesangial cell fibronectin synthesis (A) and protein
ktnase C activity (B). Mesangial cells were treated as described in Figure
3. The cells were exposed to GFX or its DMSO vehicle (0.05%) for 15
minutes before addition of U-46619 () or its vehicle (El). Values are
means SE (N = 5). P < 0.05 comparing U-46619 to its vehicle control.
+P C 0.05 vs. corresponding value without GFX.
tion (0.5 JIM) phorbol 12-myristate 13-acetate (PMA) for 18
hours. As previously reported, this results in downregulation of
PKC activity to less than 1% of control [10, 18]. After down-
regulation of PKC, a five hour exposure of MC to U-46619 failed
to increase Fn synthesis [ratio of immunoprecipitable [35S]-Fn in
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Fig. 7. Effect of atrial natiuretic peptide (ANP) on mesangial cell cGMP.
Mesangial cells were treated as described in Figure 2, ANT' () ornothing
(LI) was added, and the cells harvested after 15 minutes or 5 hours. cGMP
in cell extracts was determined by radioimmunoassay. Values are means
SE (N = 3). P < 0.05 vs. enntrol.
8-Br-cGMP, or 1 1ILM 8-Br-guanosine. Specific binding of [3H] Sq
to MC not exposed to 8-Br-compounds was 19 1 fmol/106 cells;
specific binding of [3HJ Sq to MC exposed to 1 MM 8-Br-guanosine
for one hour was 18 1 fmol/106 cells, while binding to cells
exposed to 8-Br-cGMP was 20 2 fmol/106 cells, N = 4.
Scatchard analysis of Sq binding revealed no changes in the
Vehicle 8-Br-cGMP 8-Br G affinity of the TXA2!PGH2 receptor sites following 24 hours of
1 pM 1 ,IJM exposure of MC to 8-Br-cGMP compared to control (data not
shown). These results suggest that the inhibitory actions of cGMP
Fig. 6. Effect of 8-Br-cGMP on U-46619 stimulated mesangial cellfibronec- were expressed at a step or steps distal to U-46619 receptor
tin synthesis (A) and protein kinase C activity (B). Mesangial cells were binding.
treated as described in Figure 3; 1 /.tM 8-Br-cGMP or 8-Br-guanosine was Figure 7 shows the effects of 0.1 MM ANP on the cGMP content
added 30 minutes before U-46619 () or its vehicle (LI). Values are .
* of MC after 15 minute or five hour incubattons tn the absence ofmeans SE (N = 5). P < 0.05 vs. control. +P < 0.05 vs. corresponding
value without 8-Br-cGMP. an inhibitor of cyclic nucleotide phosphodiesterase activity. cGMP
was increased approximately fivefold at 15 minutes after addition
of ANP and remained elevated through five hours. Figure 8 shows
cells treated with PMA + U-46619 to cells treated with PMA the effects of 0,1 MMANP on Fn synthesis and PKC activity in MC.
alone = 0.99 0.05; ratio in MC treated with the vehicle for PMA Exposure of MC to ANP for five hours did not significantly alter
+ U-46619 to those treated with the PMA vehicle (0.5% DMSO) basal MARCKS protein phosphorylation or Fn synthesis in MC,
alone = 1.8 0.13; N = 4]. but blocked increases in both of these parameters in response to
The effects of 1 MM 8-Br-cGMP on Fn synthesis and PKC 1 MM U-46619. Figure 9 shows the effect of 0.1 MM ANP on
activity are shown in Figure 6. 8-Br-cGMP did not significantly increases in PKC activity induced by 0.1 MM PDBu, a maximally
affect basal MARCKS protein phosphorylation or Fn synthesis. effective concentration. As shown, ANP significantly suppressed,
However, it abolished activation of PKC and stimulation of Fn but did not block, the increases in PKC activity induced by PDBu.
synthesis induced by U-46619. By contrast, 8-Br-guanosinc did not
alter any of the parameters examined (Fig. 6). The effect of
8-Br-cGMP and 8-Br-guanosine on TXA2/PGH2 receptor number The results demonstrate that the TXA2/PGH2 analogue
was determined by equilibrium binding of the TXA2/PGH2 an- U-46619 stimulates Fn synthesis in cultured rat MC. They are
tagonist Sq-29548 to MC. [3H]Sq-29548 binding was not changed consistent with the earlier findings of Bruggeman et al [7] in
by culture of MC for 60 minutes or 24 hours with 1 MM human MC. In agreement with the latter report no changes in the
Discussion
Fig. 8. Effect of ANP on U-46619 stimulated mesangial cell fibronectin
synthesis (A) and protein kinase C activity (B). Mesangial cells were treated
as described in Figure 3, with the exception that fibroneetin synthesis was
determined after 5 hour exposure to 1 LM U-46619. The cells were
incubated with 0.1 .LM ANP for30 minutes before the addition of U-46619() or its vehicle (fl). Values are means SE (N = 4). P C 0.05
comparing U-46619 to its vehicle control. +P C 0.05 vs. corresponding
value without ANP.
cell number per well were observed after 24 hour exposure to 1
LM U-46619 in rat MC. However, this finding does not preclude
effects of TXA2 on MC proliferation which may be complex [9]
and time dependent. In our studies, changes in [35S]-Fn were
routinely monitored in the cell plus matrix fraction. In previous
Fig. 9. Effect of ANP on phorbol dibutyrate (PDBu) stimulated protein
kinase C activity. For determination of protein kinase C activity mesangial
cells were treated as in Figure 3. ANP (0.1 jiM) was present for 30 minutes
before the addition of 0.1 l.LM PDBu. Phosphorylation of the 80 kDa
protein was determined 15 minutes after addition of PDBu () or DMSO
vehicle (El) (0.1%). Values are means SE (N = 3). P C 0.05 vs. vehicle
control. +P C 0.05 comparing PDBu to its corresponding value without
ANP.
studies of human MC, U-46619 has been reported to increase
newly synthesized protein found both in the cell fraction and the
medium after three to six hours [7], or alternatively to increase
cell associated labeled protein and to decrease newly synthesized
protein released into the medium after 4 to 24 hours [9]. Under
the incubation conditions used in the present studies of rat MC,
medium immunoprecipitable [35S]-Fn was a minor component of
the total; it decreased from 5.3 to 3.9% of that associated with the
cells plus matrix after 24 hour exposure to U-46619. Inclusion of
the data for medium [35S]-Fn after the four-hour pulse labeling
period would not have altered our results. Whether a longer
exposure of MC to U-46619 alters MC fibroneetin cell-matrix-
medium dynamics remains to be examined. The pattern of MC
synthesis, secretion, and matrix incorporation of newly synthe-
sized protein can vary with the degree of confluence [19] and
perhaps also with the species from which the cells are derived and
the culture conditions used. Resolution of these questions will
require further analysis by different experimental approaches than
those employed in the present study.
In the studies of Bruggeman et al [7], the response of MC to
only a single concentration of U-46619 (0.1 j.LM) was described.
Thus, a direct comparison of the present concentration response
data with these earlier results is not possible. In the present
studies of rat MC, the lowest concentration of U-46619 which was
effective in activating PKC and stimulating Fn synthesis was 0.1
p. Results in platelets have suggested that some effects of high
concentrations of TX may be expressed via non-receptor medi-
ated mechanisms [20]. This does not appear to be the case for
A
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U-46619 stimulation of PKC and Fn synthesis in MC, since a
TXA2/PGH2 receptor antagonist blocked both these actions.
Previous studies in MC have demonstrated that U-46619 activates
phospholipase C through a receptor mediated mechanism with
consequent increases in inositol phospholipid turnover, cytosolic
calcium and diacyiglycerol, and activation of PKC [11, 13, 14]. The
present results with U-46619 confirm the receptor mediated
activation of PKC in rat MC previously reported by Spurney and
co-workers [11] using the TXA2/PGH2 analogue {15-[la,213(5Z),
3a-(1E,35)4x]}-7-{3-[3-hydroxy-4-(p-iodophenoxy)-1-butenyl1]7-
oxabicyclo [2.2.1]hept-2-yl}-5-heptenoic acid (1-BOP). The cur-
rent studies also implicate activation of PKC by U-46619 as a
necessary step in the action of this agent to stimulate Fn synthesis
in MC. Thus, down-regulation of PKC by a prior 18 hour exposure
of cells to a high concentration of PMA resulted in loss of the
action of U-46619 to increase Fn synthesis. In addition, GFX, a
selective inhibitor of PKC [15], blocked both U-46619 activation
of PKC and the subsequent increases in Fn synthesis, without
adversely affecting cell viability. Calphostin C and staurosporine,
PKC inhibitors structurally distinct from GFX, had analogous
suppressive effects. We have previously demonstrated activation
of PKC and stimulation of Fn synthesis in response to low
concentrations of the phorbol ester, PDBu [10], a finding also
supportive of a role for PKC in the regulation of Fn synthesis.
The intracellular mechanisms by which activation of PKC in
MC signals increased matrix protein synthesis were not addressed
in the present study and remain to be defined. The acute increase
in Fn synthesis seen after five hours of exposure to U-46619 could
be the result of PKC directly inducing changes in the transcription
or translation of the Fn genome. However, recent studies in
vascular smooth muscle cells have suggested that the action of TX
to increase protein synthesis involves both PKC activation and
enhanced production and release of the cytokine, basic fibroblast
growth factor [21]. Gibbons, Pratt and Dzau [22] concluded that
angiotensin II induces increased TGF-13 gene expression via a
PKC dependent pathway in vascular smooth muscle cells. Simi-
larly, Nobel, Kagami and Border [23] have reported that angio-
tensin II, a known agonist of PKC [24], increases MC matrix
protein synthesis after 48 hours of exposure by stimulation of
TGF-p synthesis. Previous studies in our own [10] and other
laboratories [25] have implicated activation of PKC as a cellular
signal for the actions of high concentrations of glucose to enhance
MC synthesis of Fn and other matrix proteins. In this regard,
Ziyadeh et al have implicated TGF-/3 in the stimulation of MC
matrix protein synthesis induced by high ambient concentrations
of glucose [26]. Thus, it is possible that activation of PKC in MC
by TX, high concentrations of glucose, and other agonists of PKC
may lead to increased matrix protein synthesis, at least in part by
an indirect mechanism which involves production of autocrines
such as TGF-/3. The more prominent increases in Fn synthesis
seen after 72 hours of exposure to U-46619 compared to shorter
periods of exposure would be consistent with progressive accumu-
lation of an autocrine. However, this possibility remains to be
examined.
Whatever the precise mechanisms by which TX stimulates MC
synthesis of Fn, the present study provides evidence that this
action can be modulated by cellular levels of cGMP. Thus,
increases in cGMP, induced by either addition of 8-Br-cGMP to
MC cultures or by stimulation of endogenous cUMP production
with ANP, blocked U-46619 activation of PKC and the subse-
quent increases in Fn synthesis. These results strongly imply that
cGMP blocks U-46619 stimulation of Fn synthesis by preventing
activation of PKC. cGMP did not alter TXA2/PGH2 receptor
number or affinity in MC. Thus, cGMP likely inhibits expression
of TX actions on MC at a step or steps distal to receptor binding
of TX, but at or proximal to activation of PKC. In this regard,
cGMP has been shown to inhibit the actions of several agonists
which signal via receptor mediated activation of phospholipase C.
Thus, both exogenous cGMP and ANP suppress MC production
of endothelin induced by AVP [27]; ANP has also been shown to
suppress angiotensin II mediated protein synthesis in vascular
smooth muscle cells [28]. Hirata and co-workers [29] presented
evidence that cGMP inhibited AVP stimulation of phosphoinosi-
tide hydrolysis in vascular smooth muscle cells by inhibiting
guanine nucleotide regulatory protein (Gp) activation and the
interaction between Gp and phospholipase C. Similarly, studies in
platelets by Nguyen, Saitoh and Ware [30] suggest that cGMP
may inhibit U-46619 signal transduction at a point proximal to
phospholipase C activation, possibly also reflecting an effect of
cGMP on Gp interaction with phospholipase C. However, this
may not be the only step at which cGMP inhibits transduction of
PKC mediated cellular actions. Thus, in the present study (Fig. 9)
ANP suppressed activation of PKC by PDBu, a structural ana-
logue of diacylglycerol that interacts directly with the regulatory
unit of the enzyme [31]. Similarly, ANP has been shown to
suppress the action of phorbol ester to activate PKC in vascular
smooth muscle cells [32]. These results suggest that the inhibitory
effect of cGMP on PKC mediated substrate phosphorylation may
be complex. In addition to any action at the level of Gp-
phospholipase C activation, more direct effects of cGMP on the
regulatory and/or catalytic regions of PKC, cytosolic calcium
levels [33], or phosphatase activity directed at PKC substrates are
not excluded.
Recent studies by Bruggeman et al [8] in cultured murine
teratocarcinoma cells have demonstrated opposite effects of pros-
tacyclin and TX on mRNA levels for several matrix proteins
including fibronectin. Thus, while U-46619 increases mRNA
levels for matrix proteins, carbo-prostacyclin suppressed these
levels. The latter action of prostacyclin may have been signalled by
cAMP, although this was not specifically studied. In this regard, a
number of agents which increase cAMP levels in cultured MC,
including prostacyclin, PGE2, isoproterenol, forskolin, and 8-bro-
mo-cAMP have been shown to suppress protein synthesis and
proliferation, and to induce relaxation in cultured MC [34—40].
These actions of cAMP are analogous to those reported in
response to cOMP [35, 41—44]. Thus, both of these intracellular
signalling systems may exert directionally similar effects on matrix
protein synthesis in MC. The mechanisms by which cGMP and
cAMP influence these MC functions are not known. Actions of
both agents have been linked at least in part to a reduction in
cytosolic Ca2 and suppression of inositol phospholipid turnover
[45—49]. The recent demonstration that NO induces cyclooxyge-
nase activity [49] raises the possibility that increases in NO may
lead to enhanced generation of both cAMP and cGMP. The
potential interaction between these two cyclic nucleotides in the
control of MC protein synthesis deserves further study.
The implications of the present results for the physiologic and
pathophysiologic modulation of glomerular matrix content and
composition remain speculative. As noted above, TX may be
involved in the pathogenesis of several experimental models of
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glomerular injury [1] including that induced by diabetes mellitus
[2]. In addition to the actions of TX as a vasoconstrictor and
platelet activator, the present and earlier studies [7—9] suggest
that direct effects of TX on MC function may contribute to
glomeruloscierosis. Relatively high concentrations of U-46619 are
required to increase MC synthesis of Fn in vitro. This might reflect
a pathophysiologic rather than physiologic action of TX on MC
matrix protein synthesis in vivo, and thus one expressed only in the
presence of enhanced local concentrations of TX. This would be
consistent with observations in isolated glomeruli from diabetic
rats [3, 5] and other models of glomerular injury [1, 35], where
increased glomerular production of TX has been documented.
The capacity of cGMP, whether increased via activation of
particulate guanylate cyclase by ANP [41, 42] or via stimulation of
heme dependent cytosolic guanylate cyclase by EDRF/nitric oxide
[30, 43], to antagonize agonist stimulated vasoconstriction and
platelet aggregation are well documented. The present results
suggest that cGMP may also modulate the direct actions of TX to
stimulate MC matrix production by suppression of TX activation
of PKC. Accordingly, interactions between these two cellular
signalling systems could be important determinants of MC matrix
production in disorders in which either glomerular TX production
is increased, or in which other factors, including hyperglycemia
[10, 25], lead to activation of PKC in MC. In this regard, we have
recently observed a reciprocal relationship between TX mediated
activation of PKC and NO-dependent cGMP generation in iso-
lated glomeruli. In glomeruli from diabetic rats, TX production is
enhanced and PKC is activated, while NO-dependent basal and
cholinergic responsive cGMP generation are suppressed [3, 5, 16,
50]. Inhibitors of PKC, or TXA2/PGH2 receptor blockers, restore
the cGMP response to cholinergic stimulation in isolated glomer-
uli from diabetic rats [16]. Conversely, in normal glomeruli,
U-46619 activates PKC and suppresses the cGMP response to
cholinergic stimuli; these actions of U-46619 are prevented by
inhibitors of PKC [16]. Thus, findings in isolated glomeruli suggest
that activation of PKC suppresses NO-dependent cGMP genera-
tion. Conversely, suppression of PKC mediated MC matrix
protein synthesis by cGMP (Figs. 6 and 8) suggests that one
consequence of defective cGMP generation in the glomeruli of
diabetics may be an amplification of PKC signalled MC matrix
production.
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